{"id":"bortezomib-melphalan","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL325041","moleculeType":"Small molecule","molecularWeight":"384.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination pairs bortezomib, a proteasome inhibitor that prevents degradation of pro-apoptotic proteins and causes accumulation of misfolded proteins in cancer cells, with melphalan, a nitrogen mustard alkylating agent that cross-links DNA and induces cell death. The combination is designed to enhance cytotoxicity in multiple myeloma and other hematologic malignancies through complementary mechanisms.","oneSentence":"Bortezomib inhibits the proteasome to trigger cancer cell death, while melphalan is an alkylating agent that damages DNA in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:21.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (induction therapy in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03850366","phase":"PHASE2","title":"HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2016-03-08","conditions":"Hematological Malignancy","enrollment":15},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT03617731","phase":"PHASE3","title":"Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2018-10-18","conditions":"Multiple Myeloma","enrollment":662},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT05231629","phase":"PHASE2","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-12-13","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT01241708","phase":"PHASE3","title":"Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-04-08","conditions":"Multiple Myeloma, Auto Stem Cell Transplant","enrollment":148},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT06918002","phase":"PHASE3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients","status":"RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2025-07-09","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":824},{"nctId":"NCT00871013","phase":"PHASE2","title":"Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2009-03","conditions":"Myeloma","enrollment":160},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT06913192","phase":"PHASE1","title":"Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2025-04-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT06245629","phase":"","title":"Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-11-24","conditions":"Myeloma Multiple","enrollment":100},{"nctId":"NCT06463717","phase":"","title":"Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-12-01","conditions":"Multiple Myeloma, Minimal Residual Disease","enrollment":210},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT03188172","phase":"PHASE2","title":"MUK Nine b: OPTIMUM Treatment Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Leeds","startDate":"2017-09-28","conditions":"Multiple Myeloma","enrollment":95},{"nctId":"NCT03217812","phase":"PHASE3","title":"A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-23","conditions":"Multiple Myeloma","enrollment":220},{"nctId":"NCT04817956","phase":"PHASE2","title":"Improving Public Cancer Care by Implementing Precision Medicine in Norway","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-01","conditions":"Cancer Metastatic","enrollment":3000},{"nctId":"NCT04210791","phase":"","title":"Autologous Stem Cell Transplantation for Patients With AL Amyloidosis","status":"ENROLLING_BY_INVITATION","sponsor":"Nanjing University School of Medicine","startDate":"2010-07-01","conditions":"AL Amyloidosis, Plasma Cell Dyscrasia","enrollment":500},{"nctId":"NCT01190787","phase":"PHASE2","title":"Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":150},{"nctId":"NCT00520767","phase":"PHASE2","title":"Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-09","conditions":"Primary Systemic Amyloidosis, Light Chain Deposition Disease","enrollment":35},{"nctId":"NCT00734149","phase":"PHASE2","title":"Bortezomib With Melphalan and Prednisone for Multiple Myeloma","status":"COMPLETED","sponsor":"Duke University","startDate":"2004-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT00571493","phase":"PHASE1, PHASE2","title":"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-04-14","conditions":"Non-hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT01063179","phase":"PHASE3","title":"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":511},{"nctId":"NCT04151615","phase":"","title":"VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-11-15","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT00995059","phase":"PHASE1, PHASE2","title":"Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"","conditions":"Multiple Myeloma, Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT02440464","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT01242267","phase":"PHASE1, PHASE2","title":"Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-05-11","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT03481556","phase":"PHASE1, PHASE2","title":"Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2018-04-12","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT05558319","phase":"PHASE3","title":"NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2022-10","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":480},{"nctId":"NCT01702831","phase":"PHASE2","title":"Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-10-01","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT05218603","phase":"","title":"Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2021-11-30","conditions":"Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)","enrollment":100},{"nctId":"NCT03742297","phase":"PHASE3","title":"Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-10-22","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":462},{"nctId":"NCT00784823","phase":"PHASE1, PHASE2","title":"Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT01453101","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-09","conditions":"Multiple Myeloma","enrollment":54},{"nctId":"NCT02197221","phase":"PHASE3","title":"Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2015-01","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT01849783","phase":"PHASE2","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Margarida Magalhaes-Silverman","startDate":"2013-04-04","conditions":"Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease","enrollment":41},{"nctId":"NCT01078454","phase":"PHASE3","title":"Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11","conditions":"Light Chain Deposition Disease, Primary Systemic Amyloidosis","enrollment":11},{"nctId":"NCT01109004","phase":"PHASE3","title":"Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":758},{"nctId":"NCT05054478","phase":"PHASE2","title":"Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10","conditions":"Plasma Cell Leukemia","enrollment":29},{"nctId":"NCT00792142","phase":"PHASE2","title":"Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-01-16","conditions":"Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity","enrollment":45},{"nctId":"NCT02112175","phase":"PHASE3","title":"Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-04-30","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT01083316","phase":"PHASE2","title":"Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2009-09","conditions":"Amyloidosis","enrollment":35},{"nctId":"NCT00469209","phase":"PHASE1, PHASE2","title":"Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-06","conditions":"Myeloma","enrollment":60},{"nctId":"NCT01605032","phase":"PHASE2","title":"Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-02","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":19},{"nctId":"NCT00985907","phase":"PHASE1, PHASE2","title":"Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2004-10-28","conditions":"Multiple Myeloma, Patient Participation","enrollment":13},{"nctId":"NCT01383759","phase":"NA","title":"Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-06-24","conditions":"Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD)","enrollment":20},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT00793572","phase":"PHASE2","title":"Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-10","conditions":"Refractory Plasma Cell Myeloma","enrollment":32},{"nctId":"NCT02773550","phase":"PHASE4","title":"Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Basque Health Service","startDate":"2014-01","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT00948922","phase":"PHASE2","title":"Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-06-18","conditions":"Multiple Myeloma","enrollment":124},{"nctId":"NCT00439556","phase":"PHASE2","title":"Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-02-13","conditions":"CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm","enrollment":40},{"nctId":"NCT01818752","phase":"PHASE3","title":"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-08","conditions":"Multiple Myeloma","enrollment":955},{"nctId":"NCT03393273","phase":"PHASE2","title":"Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT04008888","phase":"NA","title":"a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-01-05","conditions":"Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma","enrollment":50},{"nctId":"NCT01191060","phase":"PHASE3","title":"Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2010-10","conditions":"Myeloma","enrollment":700},{"nctId":"NCT02145598","phase":"PHASE2, PHASE3","title":"Treatment Optimization in Patients With Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Dr. med. Lars-Olof Muegge","startDate":"2013-08","conditions":"Multiple Myeloma","enrollment":85},{"nctId":"NCT00789256","phase":"NA","title":"Low Dose Melphalan and Bortezomib for AML and High-Risk MDS","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2004-09","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":26},{"nctId":"NCT02489500","phase":"PHASE3","title":"Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2015-06","conditions":"AL Amyloidosis","enrollment":3},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT01936090","phase":"PHASE1","title":"Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-08","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":11},{"nctId":"NCT00574080","phase":"PHASE3","title":"UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-07","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00081939","phase":"PHASE2","title":"UARK 2003-33, Total Therapy III","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":303},{"nctId":"NCT01916252","phase":"PHASE3","title":"Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2013-09","conditions":"Multiple Myeloma","enrollment":460},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01548573","phase":"PHASE2","title":"Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT00642395","phase":"PHASE2","title":"Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2007-07","conditions":"Multiple Myeloma","enrollment":61},{"nctId":"NCT01206205","phase":"PHASE2","title":"Frontline Therapy in de Novo Multiple Myeloma Patients Under 65","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2009-08","conditions":"Multiple Myeloma","enrollment":31},{"nctId":"NCT01277016","phase":"PHASE3","title":"A Trial for Systemic Light-chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2011-01","conditions":"AL Amyloidosis","enrollment":110},{"nctId":"NCT00307086","phase":"PHASE2","title":"Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2005-06","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":30},{"nctId":"NCT00790647","phase":"PHASE2","title":"Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2008-06","conditions":"Multiple Myeloma","enrollment":10},{"nctId":"NCT01237249","phase":"PHASE2","title":"Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2011-02","conditions":"Multiple Myeloma","enrollment":250},{"nctId":"NCT02981199","phase":"NA","title":"Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Chen Wenming","startDate":"2016-01","conditions":"Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse","enrollment":80},{"nctId":"NCT00504101","phase":"PHASE1","title":"Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2007-06","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT02573935","phase":"PHASE2","title":"Clarithromycin in Multiple Myeloma Induction Therapy","status":"TERMINATED","sponsor":"Henrik Gregersen","startDate":"2015-01","conditions":"Multiple Myeloma","enrollment":58},{"nctId":"NCT00458822","phase":"PHASE2","title":"Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-02","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":40},{"nctId":"NCT02109861","phase":"EARLY_PHASE1","title":"Microdose Study of Melphalan, Bortezomib and Dexamethasone","status":"UNKNOWN","sponsor":"Henrik Gregersen","startDate":"2014-01","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT00799539","phase":"","title":"A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen-Ortho Inc., Canada","startDate":"","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02474563","phase":"","title":"Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2011-05","conditions":"Multiple Myeloma","enrollment":171},{"nctId":"NCT02353572","phase":"PHASE1, PHASE2","title":"Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2009-11","conditions":"Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma","enrollment":3},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01055301","phase":"PHASE2","title":"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2011-07","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT00516191","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2004-10","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00911859","phase":"PHASE2","title":"A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-06","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT00564200","phase":"PHASE2","title":"MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-11","conditions":"Multiple Myeloma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":152,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bortezomib-Melphalan","genericName":"Bortezomib-Melphalan","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bortezomib is a small molecule used in the treatment of Multiple Myeloma, Multiple Myeloma and Plasma Cell Neoplasm, and AL Amyloidosis. It is often used in combination with other treatments, such as Lenalidomide, as part of a frontline therapy regimen for de novo multiple myeloma patients under 65.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}